Skip to main content

Awakn Life Sciences Corp(AWKNF)
OTC US

Today's Change
Delayed Last Update
Day Low0.0650
Day High0.0849
Open:0.0800
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Newsfile
Awakn Life Sciences Announces Completion of Arrangement and Sale to Solvonis Therapeutics plc
Newsfile
Awakn Life Sciences Announces Shareholder Approval of Arrangement
Newsfile
Awakn Life Sciences Provides Supplemental Disclosure in Connection with Proposed Plan of Arrangement
Newsfile
Awakn Life Sciences Enters into Arrangement Agreement for The Acquisition of Awakn by Solvonis Therapeutics plc
Newsfile
Awakn Life Sciences Provides Update on R&D Programs, Progressing Novel Therapeutics for Alcohol Use Disorder and PTSD
Newsfile
Awakn Announces Positive Outcome of Pre-IND Meeting with FDA for AWKN-002 in Alcohol Use Disorder
Newsfile
Awakn Life Sciences Announces Credit Facility
AllPennyStocks.com
Biotech Micro-Cap Enters Transformational LOI, Shares Halted On News
Biotech Micro-Cap Enters Transformational LOI, Shares Halted On News
Newsfile
Awakn Life Sciences Enters into Binding Letter of Intent for Acquisition of Awakn by Graft Polymer (UK) Plc
Newsfile
Awakn Announces Promising Results from Aminoindane New Chemical Entity Pre-Clinical Program
Newsfile
Awakn Announces Opening of Four Additional AWKN-001 Phase 3 Trial Sites
Newsfile
Awakn Partners with the University of Nottingham for in Vivo Testing of Aminoindane New Chemical Entity (NCE) Pre-Clinical Program
Newsfile
Awakn Selects Eurofins Discovery for Pharmacology Testing in New Chemical Entity (NCE) Pre-Clinical Program
Newsfile
Awakn Life Sciences Announces Upsizing and Closing of Tranche of Private Placement Financing
Newsfile
Awakn Announces Key Progress in Its Aminoindane Pre-Clinical Program
Newsfile
Awakn Announces First Patient Screened in Phase 3 Clinical Trial of AWKN-001 for Severe Alcohol Use Disorder
Newsfile
Awakn Life Sciences Announces Closing of Tranche of Private Placement and Warrant Extension
Newsfile
Awakn Life Sciences Provides Update on Aminoindane New Chemical Entity Patent Portfolio
Newsfile
Awakn Life Sciences Announces Collaboration Agreement with Graft Polymer (UK) PLC
Newsfile
Awakn Life Sciences Announces Closing of Tranche of Private Placement
Newsfile
Awakn Life Sciences Discusses Filing of Financial Statements
Newsfile
Awakn Life Sciences Announces Closing of Tranche of Private Placement
Newsfile
Awakn Life Sciences Announces Launch of Licensing Partnership Agreement with Oklahoma Based Clinic
Newsfile
Awakn Life Sciences Announces Listing on the Canadian Securities Exchange
Newsfile
Awakn Life Sciences Announces Conditional Approval of CSE Listing
Newsfile
Awakn Life Sciences Completes Successful Investigative Study to Establish Dissociative Effect of a Proprietary Sublingual S-Ketamine Oral Thin Film Formulation in Harmful Drinkers
Newsfile
Awakn Life Sciences Enters Global Licensing Agreement For Proprietary Sublingual S-Ketamine Formulation With LTS
Newsfile
Awakn Life Sciences Provides Corporate Update
Newsfile
Awakn Life Sciences Receives Regulatory and Ethical Approval for Phase III Clinical Trial of AWKN-P001
Newsfile
Awakn Life Sciences Announces Receipt of Notice of Non-Compliance with Cboe Exchange Continued Listing Requirements
Newsfile
Awakn Life Sciences Engages Orphan Insight Ltd. to Advance Market Access, Pricing, and Reimbursement Strategies for AWKN-P001 Targeting Severe Alcohol Use Disorder
Newsfile
Awakn Life Sciences Completes MDMA Zydis(R) ODT Feasibility Study

Profile

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.